Citrel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citrel

Property Description
Active Ingredient Pantoprazole sodium
Pharmacological Class Proton Pump Inhibitor (PPI)
Primary Forms Delayed-release oral tablets, Intravenous solution
Origin Synthetic organic compound
General Purpose Sustained reduction of stomach acid

What Type of Medication is Citrel (Pantoprazole)?

Citrel is the trade name for a prescription medication whose sole active ingredient is Pantoprazole. It is classified as a Proton Pump Inhibitor (PPI), a potent pharmacological class designed for the management of conditions involving excessive or problematic gastric acid. The molecule is a synthetic organic compound derived from the benzimidazole chemical group.

Pantoprazole is an agent for sustained gastric acid suppression. Citrel’s fundamental purpose is to support the healing processes associated with acid-related damage by maintaining a consistently low-acid environment.


Composition and Delivery Forms of Citrel

Citrel is a single active ingredient product, containing Pantoprazole sodium, and is manufactured for both oral and intravenous administration. This dual availability is key for flexibility in patient care, especially the intravenous form, which is essential when oral intake is compromised.

Its most common forms, the delayed-release tablets and granules, feature a specialized coating. This design is critical for ensuring the Pantoprazole is protected from stomach acid and reliably absorbed into the bloodstream. This specialized delivery mechanism is required for the medication to reach its site of action effectively.


General Function: How Citrel Works on Stomach Acid

The primary function of Citrel is to achieve a profound and sustained reduction in the production of hydrochloric acid within the stomach. It achieves this by selectively binding to the H+/K+ ATP pumps—the proton pumps—that are responsible for secreting acid into the stomach lining.

By irreversibly deactivating these pumps, Citrel effectively shuts down the final step of the acid production pathway. This action, characteristic of the PPI class, results in a suppression of gastric acid secretion, offering the digestive system the necessary prolonged period of relief from high acidity to facilitate recovery and healing.

Regulatory References

  1. Proton Pump Inhibitor (PPI)

What side effects are possible with Citrel?

Possible Side Effects and Safety Information

The safety profile for Citrel (Pantoprazole) is formally documented in regulatory sources and categorized by the frequency and physiological system affected. Adverse reactions are grouped by System-Organ Class (SOC), including effects on the Gastrointestinal, Nervous, Blood and Lymphatic, and Skin systems.

Officially documented adverse reactions are categorized by frequency:

  • Common: Adverse effects reported frequently in clinical trials include headache, dizziness, diarrhea, nausea, abdominal pain, flatulence, and joint pain (arthralgia). The development of benign fundic gland polyps is also classified as common.
  • Uncommon: Effects reported less frequently include sleep disturbances, dry mouth, rash, itching, malaise, and fatigue. An increased risk of bone fracture of the hip, wrist, or spine is noted, particularly in older adults and with long-term use.
  • Not Known: Post-marketing events with frequency that cannot be estimated include Hypomagnesaemia (low magnesium levels), which is typically associated with use longer than three months, and Acute Tubulointerstitial Nephritis (TIN), a form of kidney inflammation.

Certain risks are associated with long-term exposure. In addition to bone fracture, prolonged use (e.g., beyond one year) is associated with an increased risk of B-12 deficiency and Atrophic Gastritis. Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are rare but documented serious adverse reactions. The regulatory label also stipulates that symptom relief does not rule out the presence of gastric malignancy, and therapy may be associated with an increased risk of Clostridium difficile-associated diarrhea.

Overdose and Emergency Response

Overdose and When to Seek Help

The specific, officially documented overdose profile for a product named “Citrel” is not available in standard government regulatory databases (such as the FDA, EMA, or Health Canada). Regulatory bodies mandate specific procedures for managing acute toxicity, which depend entirely on the substance's known pharmacological effects.

Should an overdose involving this substance be suspected, the immediate action is to seek emergency medical attention. Overdose, whether intentional or accidental, can lead to severe adverse health outcomes, and immediate assessment by medical professionals is essential. Do not wait for symptoms to appear or worsen before seeking help.

Required Emergency Action

Category Action Mandate (Regulatory Standard)
Immediate Step Contact a Poison Control Center or Emergency Services (911/112/999) right away.
Critical Information Be prepared to state the amount taken, the time of ingestion, and any observed symptoms.

Manifestations and Risk Factors

Any overdose may potentially affect major organ systems, including the central nervous system, and can progress rapidly. The severity of an overdose is influenced by the quantity ingested and individual patient factors. Urgent medical attention is required if there is any evidence of: unusual confusion, unresponsiveness, severe vomiting, or difficulty breathing. Prompt intervention is critical to manage life-threatening complications and begin supportive care.

Therapeutic Uses of Citrel

Quick Facts on Citrel's Uses

  • Support for Microbial Balance: May be utilized to help maintain a healthy microbial environment.
  • Antioxidant Properties: Has been investigated for its capacity to assist the body's natural antioxidant processes.
  • Inflammatory Response: Is associated with the modulation of certain inflammatory markers.

Citrel is an ingredient with properties that support the management of certain microbial loads, contributing to the maintenance of normal bodily functions.

Citrel possesses characteristics that contribute to antioxidant activity. These actions may play a role in helping to safeguard cells from the effects of oxidative stress. The substance is also used in areas that help support a balanced inflammatory response.

As a compound, Citrel has a history of safe use when used as a flavoring agent in food.

Citrel is commonly utilized in preparations designed to assist with overall wellness and to promote the stability of internal systems.

Eligibility and Restrictions for Use

Eligibility for Citrel (Pantoprazole) is defined by strict regulatory criteria based on patient characteristics and pre-existing conditions.

Contraindications and Restrictions

Populations who Must Not Use Citrel

Citrel is strictly contraindicated for patients with a known hypersensitivity to the active ingredient, Pantoprazole, to any component of the formulation, or to the entire class of substituted benzimidazoles. Use is also prohibited for patients concurrently receiving rilpivirine-containing products.

Age and Organ Restrictions

The medicine is officially approved for use in adults for all labeled conditions. Pediatric eligibility for the oral form is restricted to children 5 years of age and older; use in younger children is not established. Patients with severe hepatic impairment (liver issues) have restricted use and must not exceed a 20 mg daily dose, while no adjustment is required for patients with renal impairment.

Pregnancy and Lactation

Use during pregnancy is generally not recommended and should be avoided unless clearly necessary. For nursing mothers, a regulatory decision is required to either discontinue breastfeeding or discontinue the medicine, due to its excretion into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory labeling outlines several types of interactions that affect the absorption, systemic exposure, or overall pharmacological effect of Citrel. These statements govern the required administration approach for co-medications.

Interaction Type Officially Documented Effect & Substance Categories
Exposure-Altering Co-medications Co-administration with potent inhibitors of key metabolic pathways (e.g., certain CYP enzymes) significantly increases Citrel's systemic exposure (AUC). Co-administration with potent inducers of the same pathways significantly decreases systemic exposure.
Pharmacodynamic Risk Combining Citrel with other medicinal products that share certain physiological effects (e.g., agents that prolong the QTc interval) results in an officially documented, heightened risk for specific adverse outcomes.
Non-Drug Agents & Absorption Ingesting certain substances, such as specific polyvalent cation-containing products (e.g., antacids, iron supplements) or chelation agents, may impair the absorption of Citrel, thereby reducing its effectiveness.

These documented interactions place specific constraints on concomitant use. The official profile for strong exposure-altering agents requires either monitoring of plasma levels or avoidance to ensure predictable efficacy and safety. Absorption-impairing substances, including certain over-the-counter products, require a mandated time-separation rule (e.g., administering Citrel several hours before or after the interacting agent) as explicitly stated in the regulatory documentation. Population-specific instructions are also provided, primarily for individuals with documented pharmacogenetic variations (e.g., poor metabolizers) or those already on co-medications that elevate risks.

Mechanism of Action

How Citrel Works: A Mechanistic Overview

Selective Enzyme Inhibition and Intracellular Signaling

Citrel functions as a selective inhibitor of the Phosphodiesterase 4 (PDE4) enzyme, particularly within immune and airway smooth muscle cells. This interaction prevents PDE4 from hydrolyzing the crucial second messenger, cyclic Adenosine Monophosphate (cAMP). The resulting increase in intracellular cAMP levels activates Protein Kinase A ( PKA), modifying early molecular steps that influence subsequent systemic regulatory events.


Modulation of Cellular Processes

This cascade influences two distinct systems. In immune cells, the mechanism modulates key pathways associated with heightened signaling by dampening the activity of pro-inflammatory transcription factors, such as NF-kappa B, and reducing the release of key inflammatory mediators (cytokines/chemokines). This process influences the regulation of cell activity within pathways characterized by heightened signaling.


Physiological Adjustment

In the airway smooth muscle, the elevated cAMP promotes the sequestration of calcium ions. This affects the regulation of muscle tone, leading to the relaxation of the bronchial smooth muscle. The overall effect is a specific physiological adjustment that reduces the state of muscular contraction and influences inflammatory cell function.

Dosage and Administration Information

Citrel (pantoprazole) is administered via two primary routes: oral administration, using delayed-release tablets or granules, and intravenous (IV) injection or infusion, which is generally reserved for short-term use in clinical settings when oral intake is compromised.

The standard adult dosing regimen for conditions like erosive esophagitis (EE) is 40 mg taken once daily. For pathological hypersecretory conditions, the dose is higher, often starting at 40 mg taken twice daily, with flexibility for individualized adjustment. The frequency is predominantly once daily for long-term maintenance and acute standard treatment.

Proper administration depends on the form. The delayed-release tablets must be swallowed whole to preserve the coating and ensure correct absorption; they may be taken without regard to food. Conversely, the oral granules or suspension are administered approximately 30 minutes prior to a meal. The IV form is used for a short duration, typically 7 to 10 days, after which a transition to oral therapy occurs.

Dosage adjustment applies to specific populations. For patients with severe hepatic impairment, the maximum daily dose generally does not exceed 20 mg. In cases where a dose is missed, the standard procedure is to take the dose as soon as possible, or to skip it if it is near the time for the next scheduled dose, without taking two doses concurrently.

Recent Clinical Evidence

Research evidence / Overview of studies for Citrel

Evidence for Healing and Managing Acid-Related Damage

Clinical research involving Citrel has focused heavily on conditions linked to high stomach acid. The evidence base primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews, which represent high-quality types of clinical evidence focused on the measurement of symptoms over defined periods.

Research examined outcomes related to healing damage in the food pipe, known as Erosive Esophagitis (EE). Studies monitored healing rates using internal visual examinations and used patient-reported outcomes describing perceived discomfort. Studies reported measurements of mucosal restoration across different severity grades of EE in the populations studied. The evidence also includes studies exploring symptom patterns for individuals with Symptomatic GERD who experience discomfort without visible damage. These studies monitored data and reported patterns related to a shift in the perceived discomfort during the study's observation intervals.

Research on Supporting H. Pylori Eradication

Citrel was evaluated in trials as a necessary component of a multi-drug regimen designed to address peptic ulcers associated with the Helicobacter pylori bacteria. Research examined whether this combination could achieve the successful eradication of the bacteria and subsequent healing of the ulcers. Studies reported specific eradication rates for the multi-drug regimen, with findings varying based on the combination of antibiotics used in the trial.


Evidence for Prevention and Long-Term Use

Citrel was also studied for its role in long-term maintenance and prevention. For patients whose EE has been healed, trials extending up to one year were conducted to monitor the prevention of damage recurrence. Studies examined how patients maintained healing status, reporting different rates of healing recurrence during the follow-up periods. Research also examined studies exploring the use of Citrel in patients who required continuous NSAID therapy to assess the occurrence of ulcers, reporting the occurrence of new ulcers was less frequent in the group studied with Citrel.

What is Still Uncertain in the Research Landscape

One primary limitation is that long-term effects are not fully established regarding continuous use over many years for all patient groups. Follow-up durations were limited in some of the initial high-quality trials, and certainty remains low regarding outcomes after several years. Additionally, sample sizes were modest in studies for very rare conditions like Zollinger-Ellison Syndrome (ZES), meaning the results apply only to the limited populations studied.

Frequently Asked Questions (FAQ)

Common questions about Citrel (FAQ)

Q: What happens if I miss a scheduled time to use Citrel?

A: Regulatory guidance on a missed dose generally states that the dose may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the regulatory information indicates skipping the missed dose and returning to the regular schedule. Taking two doses concurrently is strictly prohibited.

Q: Does Citrel cause tiredness or drowsiness after taking it?

A: Official safety documents list fatigue and sleep disturbances as uncommon adverse effects. General tiredness is also commonly reported in clinical data gathered from patient populations.

Q: Is it normal to feel slightly dizzy when starting Citrel?

A: Official adverse reaction data includes dizziness as a common side effect associated with use. This effect is documented in official regulatory sources.

Q: Is it possible for Citrel to interact with herbal supplements?

A: Regulatory safety information warns against the co-administration of Citrel with certain herbal supplements, such as St. John’s wort, as they may reduce the medicine's effectiveness. Regulatory documents recommend transparency regarding all supplements being used.

Q: Does Citrel interact with caffeine or alcohol?

A: Regulatory documents advise caution with substances that may impair absorption. Separately, general guidelines for managing the acid-related conditions that Citrel treats often suggest limiting alcohol and caffeine, as these substances can stimulate stomach acid production and potentially counteract the therapeutic effect.

Q: Do patients typically need to adjust their diet when starting Citrel?

A: Administration instructions for the oral granule form require it to be taken approximately 30 minutes prior to a meal. While no universal diet is mandated, general treatment guidelines often suggest limiting foods that are known to trigger acid-related symptoms, such as high-fat or spicy foods.

Q: Is Citrel the same type of medicine as [similar common drug name]?

A: Citrel is classified as a Proton Pump Inhibitor (PPI). This is the same pharmacological class as other common medicines used for the sustained suppression of stomach acid.

Q: How quickly should I expect Citrel to start working?

A: Clinical data suggests that the therapeutic effect may begin to be observed within a few days. However, achieving the full intended symptomatic relief and sustained healing may take up to four weeks of consistent use.

Q: Can Citrel be taken if I am already taking over-the-counter pain relievers?

A: Official safety information lists specific drug-drug interactions. While Citrel is sometimes studied for use alongside pain relievers like NSAIDs, there are no official contraindications for co-administration with basic over-the-counter pain relievers listed in the main warnings.

Q: Are there any common foods or drinks that should be avoided with Citrel?

A: Regulatory labeling requires time separation from substances containing polyvalent cations (such as certain iron or antacid supplements) as they can impair absorption. Beyond this, general guidance for the underlying condition often suggests limiting foods and drinks that commonly trigger acid-related symptoms.

Q: What is the average duration of time a person takes Citrel?

A: Official labeling states that the standard recommended short-term course for healing erosive esophagitis is typically up to 8 weeks for adults. The intravenous form is generally limited to 7 to 10 days of use.

Q: Can older adults use Citrel, or is it only for younger patients?

A: The medication is approved for use across the adult population. However, official safety information indicates that long-term use in older adults is associated with an increased risk of bone fracture.

Q: Is Citrel considered a long-term treatment or short-term only?

A: Citrel is officially indicated for short-term treatment (up to 8 weeks) for healing purposes. It is also indicated for long-term maintenance for specific severe conditions, such as Zollinger-Ellison Syndrome.

Q: Is there a generic version of Citrel available?

A: Yes, the active ingredient in Citrel, pantoprazole sodium, has been approved by regulatory bodies for the availability of generic versions.

Q: How long does Citrel stay in your system?

A: The duration of the drug's intended therapeutic effect on acid suppression persists longer than 24 hours. This is because its action on the acid-producing pumps is irreversible, requiring the synthesis of new pumps to fully restore acid secretion.

Q: What percentage of people experience the most commonly reported side effect of Citrel?

A: Regulatory documents primarily categorize adverse reactions by their general frequency (e.g., Common or Uncommon). While specific clinical trials may cite percentages for individual effects, a universal percentage for the 'most common' effect is generally not published in official labeling.

Q: Does Citrel require any special blood monitoring while taking it?

A: Routine, mandatory blood monitoring is not required for general use. However, official warnings state that patients on long-term therapy may require monitoring of magnesium levels due to the reported risk of hypomagnesaemia (low magnesium).

Q: Is Citrel known to be habit-forming or addictive?

A: According to official safety communications, Citrel is not classified as addictive or habit-forming. While discontinuation after long-term use can sometimes lead to a temporary return of symptoms, this is a physiological effect, not an addiction.

Q: Is it typical for Citrel's effects to fade over time?

A: Long-term use in official maintenance studies has been shown to be effective for managing specific chronic conditions. This indicates that the therapeutic acid-suppressing effect is generally sustained over time while the medicine is being used as indicated.

Q: Can someone who has allergies to other medicines still use Citrel?

A: The official regulatory contraindications are specific to a known hypersensitivity to the active ingredient (pantoprazole) or other medicines of the substituted benzimidazole class. Allergies to medicines in other drug classes are not typically listed as a direct contraindication.

Q: Does Citrel affect blood pressure or heart rate?

A: Citrel is not generally noted in regulatory documents to affect blood pressure. However, official post-marketing reports have included a fast, irregular, or pounding heartbeat as an reported adverse reaction.

Q: Is the main purpose of Citrel to cure a condition or manage symptoms?

A: Official indications show a dual purpose. The medicine is indicated for promoting the healing of acid-related damage (such as erosive esophagitis) and for the management of symptoms related to high acidity.

Q: What is the earliest age at which a patient can be prescribed Citrel?

A: Official regulatory documents indicate that the oral form of Citrel is authorized for use in pediatric patients five years of age and older for the short-term treatment of erosive esophagitis.

Q: What level of research support does Citrel have compared to other drugs in its class?

A: Official pharmacological data indicates that Citrel has a lower potential for metabolic drug interactions than some other medicines in its class. This is due to its differing primary metabolism pathway.

Q: Are there specific times of day that Citrel is described as being best used?

A: Official instructions for the granule form mandate administration prior to a meal. Clinical guidance for once-daily dosing frequently suggests taking the oral tablet first thing in the morning.

Q: Can Citrel be used safely by people with pre-existing mental health conditions?

A: Official post-marketing experience has included reports of psychiatric adverse reactions such as anxiety, sleep disorders, and confusion (and aggravations). Regulatory documents advise caution regarding these reported events.

Q: Are there different forms of Citrel available, such as liquid or chewable tablets?

A: The official regulatory forms include delayed-release tablets, granules for oral suspension (which can be mixed with liquid), and an intravenous (IV) solution. There is no officially defined chewable tablet form.

Q: Is it common for people to take Citrel for a lifetime?

A: Official safety warnings emphasize the use of the shortest duration of therapy needed. While long-term use is indicated for specific severe chronic conditions, it is not the common course for all patients.

Q: Does Citrel come with a specific patient information leaflet?

A: Yes, as a prescription medicine, regulations require that a specific Medication Guide (or Patient Information Leaflet) is made available with every new or refilled prescription.

Q: Is Citrel known to cause any skin reactions or rashes?

A: Regulatory documents list minor skin reactions such as rash and itching as uncommon side effects. Rare but very serious skin reactions (Severe Cutaneous Adverse Reactions) are also officially documented.

Q: Why is Citrel sometimes prescribed for different conditions?

A: Official indications cover a range of conditions related to problematic stomach acid. These include promoting the healing of acid-related damage, managing symptoms of reflux, and treating specific hypersecretory conditions.

Q: How does the FDA classify the safety level of Citrel for use?

A: The FDA previously assigned the medicine to Pregnancy Category B. The agency's current labeling requires a summary of risks rather than a single category, noting observational studies found no association with major birth malformations.

Q: Does Citrel impact fertility or reproductive health?

A: Official nonclinical studies on reproduction and fertility have revealed no evidence of impaired fertility or harm to reproductive performance. Clinical guidelines and official sources do not suggest it impacts reproductive health.

How should Citrel be stored and disposed of?

Official Storage and Disposal Profile

The storage and disposal requirements for Citral are strictly defined by regulatory documents to maintain stability and prevent environmental harm.

Storage Component Official Requirement
Temperature and Light Keep in a cool place (e.g., refrigerated at 2-8 C), away from heat, ignition sources, and direct light (sunlight/UV).
Container Integrity The container must be kept tightly closed in a dry and well-ventilated area, protected from air/oxygen and incompatible materials (e.g., strong acids or bases).
Handling Requires good ventilation and measures against static discharges. Contaminated cloths must be put in fireproof containers for disposal.
Disposal Classified as hazardous waste. Contents and container must be disposed of at an approved special waste collection point according to regional regulations. Do not release into drains, surface water, or the environment due to aquatic toxicity.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citrel found in:

A-Z Index: